Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects the brain, leading to cognitive decline and memory loss. It is the most common cause of dementia, a syndrome characterized by a decline in cognitive function that interferes with daily life.
Currently, there is not significant leading product on the market, and the competition landscape for AD diagnostic reagents is relatively good.
In the future, with the approval of more accurate mass spectrometry and other kits, the application of combined detection methods, and the approval of more AD treatment drugs, the AD diagnostic industry has huge development potential, and the market space may further expand.
The cerebrospinal fluid (CSF) biomarkers, that were first developed by Fujirebio more than 25 years ago, have evolved over time from research biomarkers into specialized diagnostic testing tools, and from manual usage by early adopters to a widespread implementation in fully automated routine testing today.
Diagnosis for Alzheimer's disease using CSF samples allows the detection of four proteins: two forms of amyloid (Aβ1-42 and Aβ1-40) proteins and two forms of Tau (Total Tau and phospho-Tau) proteins.
If a patient has Alzheimer's disease, then these proteins will be present in abnormally low (Aβ1-42 and Aβ1-42/Aβ1-40 ratio) and high (Total Tau and phospho-Tau) levels.
The Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio will even be low long before the symptoms of the disease start to show.
In the clinical community today, there are high hopes for the use of blood-based testing for even simpler and potentially more widespread testing for Alzheimer's disease in clinical routine.
The global Early Diagnosis Kit For Alzheimer's Disease market size is projected to grow from US$ 122 million in 2024 to US$ 200 million in 2030; it is expected to grow at a CAGR of 8.6% from 2024 to 2030.
- Segmentation by Type:
- Blood
- CSF
- Others
- Segmentation by Application:
- Medical
- Research
- Market by Region:
- Americas
- APAC
- Europe
- Middle East & Africa
- Companies coverage:
- Fujirebio
- Quanterix
- Roche Diagnostics
- Revvity
- People Bio
- Easund Bio-tech and Pharmakea
- MagQu
- Solgent
- Sysmex
- Fujifilm
- Immuno-Biological Laboratories
- Shenzhen Anqun Bioengineering
- Amoneta Diagnostics
- Key Questions Addressed in this Report
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market